BMS is best known as an early pioneer of checkpoint inhibitor therapies, which work by flipping a biochemical switch on tumour cells that suddenly makes them visible to the immune system ...
BMS said it had invested in Israel-based Compugen ... Checkpoint inhibitors work by flipping a chemical switch – PD-1 – that allows the body’s immune system to recognise cancer, and calling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback